{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9"},{"groupId":"OG001","value":"16.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"Low level of disease activity was measured by criteria for ASAS partial remission, defined as a value below 2 on a scale of 0 to 10 cm in each of the 4 ASAS domains: patient's global assessment of disease activity, total back pain, function (BASFI), inflammation.","groups":[{"description":"Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.","id":"OG000","title":"Group 1: Placebo Then Golimumab"},{"description":"Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.","id":"OG001","title":"Group 2: Golimumab"}],"paramType":"NUMBER","populationDescription":"FAS included all participants who were randomized in the study.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"Percentage of Participants With Low Level of Disease Activity (ASAS Partial Remission) at Week 16","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}